Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death and is on the increase worldwide. Hepatocellular carcinoma results from chronic liver disease and cirrhosis most commonly associated with chronic hepatitis B (HBV) or hepatitis C (HCV) infection. The highest incidences of HCC are found in China and Africa, where chronic HBV infection is the major risk component. In the United States, Europe and Japan, the significant increase in HCC and HCC-related deaths within the last three decades is mainly attributed to the rise in the number of HCV-infected individuals; smaller increases of HCC are associated with HBV. Given that HCV and HBV infection account for the majority of HCCs, therapeutic and prophylactic approaches to control or eliminate virus infection may prove effective in reducing the occurrence of HCC. Although anti-viral therapies exist for both HBV and HCV infections, they are ineffective for a significant number of patients. In addition, some treatments such as interferon therapy are dose limiting owing to toxic side effects. Clearly, new approaches are needed. RNA interference (RNAi)-based approaches may meet this need and have already shown promising preclinical results in cell culture and animal models. Although this paper focuses on the potential of RNAi as a prophylactic for HCC development, the potential use of RNAi-mediated approaches for HCC therapy will also be discussed.
Introduction
Chronic hepatitis B and C infections are the largest risk factors associated with the development of hepatocellular carcinoma (HCC). Worldwide, approximately 20-40% of individuals chronically infected with hepatitis B virus (HBV) will die from liver disease and HCC, whereas 5-7% of those chronically infected with hepatitis C virus (HCV) will die from these complications. The ability to prevent infection and/or resolve established infections would therefore significantly reduce new cases of HCC that arise each year. Although an effective vaccine for HBV has been available for 20 years, new infections in the US adult community continue to increase at a rate of 78 000-80 000 a year. This is likely owing to the fact that the vaccine is underutilized by the adult population. A vaccine is not currently available for HCV. Small-molecule therapies and interferon treatment are available for both viral infections, but these therapies suffer from a number of drawbacks including the selection of drug-resistant mutants, toxicity and limited efficacy. A promising new class of therapeutics based on RNA interference (RNAi) technology has already demonstrated efficacy in preclinical studies and has shown the potential to overcome many of the limitations associated with current therapies. The use of RNAi-based therapeutics as anti-hepatitis drugs is the main focus of this paper.
RNA interference is a phenomenon in which genes are silenced in a sequence-dependent manner at the level of mRNA degradation (Figure 1) (Fire et al., 1998; Lau et al., 2001 ). Short dsRNA (double-stranded RNA molecules), of about 19-23 bp (known as short interfering RNAs or siRNAs), are involved in mediating the degradation of mRNA (Hamilton and Baulcombe, 1999; Zamore et al., 2000) . Single RNA strands derived from these siRNAs stably associate with RNA-induced silencing complexes (RISC) found within cells (Gregory et al., 2005; Matranga et al., 2005; Rand et al., 2005) . Once bound to an siRNA, RISC becomes activated and is capable of binding to mRNAs that share significant sequence homology to the bound siRNA. This binding is mediated by Watson-Crick base pairing between the two RNAs. Activated RISC is then capable of degrading the target RNA (Hammond et al., 2001 ). The process is catalytic and once activated, RISC is thought to potentiate the degradation of thousands of target mRNA molecules.
Because RNAi is an innate phenomenon that has been shown to occur in all cell types examined, it can theoretically be harnessed to silence selected genes for therapeutic purposes. RNA interference-based therapeutics may be designed to target viral genes and/or genes associated with disease including cancer. Introduction of effector siRNAs into cells has typically been performed in one of two manners. Chemically synthesized siRNAs have been exogenously delivered to cells through transfection or electroporation in cell culture or into animals through intravenous (i.v.) or local injection. Intracellular production of siRNAs has been achieved through the delivery of plasmids or viral vectors containing expression units for short hairpin RNAs (shRNAs) in which the siRNA is contained and processed from one of the stems of the hairpin. Both types of siRNA technologies offer certain advantages and suffer from distinct limitations. The use of siRNAs theoretically allows one to deliver a known quantity of these effector molecules to cells. In addition, siRNAs have an advantage over shRNA expression vectors in that they do not need to be taken up by the nucleus in order to exert an effect. The persistence of unmodified siRNAs has been shown to be limited however, owing to instability of unmodified RNA, and therefore frequent dosing will likely be needed to maintain efficacy in a therapeutic setting. Although certain RNA modifications have been shown to increase the stability of siRNA, some of these modifications result in loss of siRNA activity. The ideal modifications for therapeutic siRNAs will therefore need to balance stability with efficacy. The use of shRNA expression plasmids or viral vectors does not suffer from similar stability problems and can be used to express large quantities of shRNA intracellularly over extended periods of time. In addition, a single expression vector can be designed to encode for multiple shRNAs, thereby increasing the potency of the product. Although, multiple chemically synthesized siRNAs can theoretically also be used, regulatory requirements necessitate the testing of individual siRNAs in clinical trials before cocktails of siRNAs can be used.
Both exogenously administered siRNAs and endogenously expressed shRNAs have been shown to reduce the RNA levels of pathogenic animal viruses. A wide variety of viruses are susceptible to RNAi (for a review see Leonard and Schaffer, 2005) . For use in the clinic, the ability to deliver the RNAi molecule (siRNA or vector) to the infected cell will be of utmost importance and the challenge for researchers is to achieve even a fraction of the success in vivo that has been demonstrated in various cell culture models.
Both HBV and HCV have been shown to be amenable to downregulation by RNAi (Radhakrishnan et al., 2004) . This inhibition has been achieved using both siRNAs and vector-mediated RNAi. The following review will discuss these results and the hurdles that face the development of RNAi-based therapeutics for the treatment of hepatitis B and C. In addition, the potential use of RNAi-based therapy for the treatment of HCC will also be discussed.
RNA interference as a therapy for chronic hepatitis B virus infection
Hepatitis B virus is an attractive target for the development of RNAi-based therapeutics given the limitations of current therapies and the poor patient response rate to these therapies. Although oral nucleoside analogues such as lamivudine and adefovir significantly lower viral titers and have shown some promise for the treatment of chronic hepatitis B, they do little in the way of decreasing HBV antigen load (Lau et al., 2000; Papatheodoridis et al., 2002) . Reduction of antigenemia is crucial, as antigenemia is the major factor in the development of liver disease. Liver pathology associated with HBV infection is primarily immune-mediated and is thought to result from cell-mediated immune responses directed against infected hepatocytes. During chronic infection, HBV DNA is frequently found to be integrated into host DNA in a form that can be transcribed by host RNA polymerase II (pol II). Transcription of these integrants, most of which encode HBV X protein and HBsAg, and transcription of episomal HBV covalently closed circle (cccDNA) result in significant expression of HBV antigens that contribute to antigen load within infected cells (Figure 2 ). Even after reduction of viral titer by oral nucleoside analogues, antigens continue to be expressed from integrants and persisting cccDNA allowing hepatocytes to remain susceptible to immune attack. The chronic inflammation induced by the immune response to persistent antigen expression is thought to contribute to the development of HCC. Therefore, treatments that target antigen expression as well as viral replication offer a significant advantage over existing treatment options, because they would decrease the visibility of hepatocytes to the immune system thereby decreasing the severity of chronic inflammation/hepatitis and secondarily preventing the development of HCC. Such therapies have the potential to be beneficial for healthy carriers as well, a subset of patients who are at risk of developing chronic active hepatitis but for whom no current therapy exists (Mendy et al., 1999) . In addition, a subset of patients exhibiting non-immune-mediated liver pathology caused by L antigen over expression (Huang and Yen, 1993) is also likely to benefit from treatment.
In the absence of a vigorous immune response to destroy antigen-harboring hepatocytes, elimination of viral antigen can only be achieved through methods that prevent antigen expression. Therapies employing RNAi either alone or in conjunction with antiviral therapies are ideal in that inhibition of viral replication and downregulation of antigen expression could be induced simultaneously and by different mechanisms. Based on the immunopathogenesis of HBV-associated liver disease, resolution of HBV infection and antigen expression by non-immune mediated mechanisms such as RNAi would be ideal. RNA interference-based strategies are ideal in another way: the selection of escape mutants can be avoided. Unlike small-molecule therapeutics, which target a specific viral activity and hence a specific portion of the virus, RNAi therapeutics can be devised to cover multiple if not all regions of the virus, making it difficult if not impossible for the virus to generate viable escape mutants. Antigenemia also plays a role in viral persistence. The high amount of surface antigen particles expressed in chronically infected patients is believed to interfere with the production of a resolving surface Antigen (sAg)-specific humoral response. Early antigen (eAg), which is not needed for viral infection, is believed to play a role in immunotolerance . Therefore, reduction of both of these antigens by RNAi should enable the immune system to mount a resolving immune response to HBV infection.
In vitro models Evaluation of siRNA efficacy and nucleic acid delivery paradigms has been enabled by the existence of relevant cell culture models and in vivo mouse models. As HBV can not infect cells in culture, in vitro proof of concept studies have focused on delivery of HBV-specific siRNAs into cells transfected with infectious HBV clones (Hamasaki et al., 2003) or into cells stably expressing wild-type or lamivudine-resistant HBV virus (Shlomai and Shaul, 2003; Ying et al., 2003) . A number of RNAi effector molecules designed to target different regions of HBV have been shown to be effective, indicating that a multitude of different siRNAs and shRNAs can be potentially utilized for treating HBV. Results indicate that both HBV-specific siRNAs and pol III (Zhang et al., 2004b; Guo et al., 2005) and pol II (Ren et al., 2005) expressed shRNAs lead to significant reductions in HBV replication and viral protein expression. These reductions are RNAi mediated and are not associated with a nonspecific interferon response (Ren et al., 2005) . In one study comparing RNAi with lamivudine, Guo et al. (2005) have shown that expressed siRNAs targeting the polymerase and surface antigen mRNAs are effective at reducing viral mRNA and HBsAg production in HepG2.215 cells, whereas, as expected, the polymerase inhibitor lamivudine reduced the load of core-related DNA but did not affect RNA or surface antigen levels. These results indicate a potential advantage of RNAi-based therapies over existing treatment modalities in that antigenemia and viral replication are both inhibited.
In vivo models In vitro experimentation has proven the effectiveness of RNAi for targeted knockdown of HBV gene expression and indicates that the virus itself is amenable to inhibition by RNAi. For use in therapeutic applications, however, delivery of siRNAs or RNAi expression vectors to hepatocytes of the liver in a clinically relevant format is a major obstacle. For in vivo delivery, siRNA, DNA and viral vectors must survive the transit through the circulatory system, avoid significant uptake by nonhepatocytes, pass through the small fenestrae (150 nm in diameter) of liver sinusoids and be taken up by hepatocytes while avoiding lysosomal degradation.
Hydrodynamic delivery. To circumvent these delivery issues and enable studies on RNAi function in vivo, studies in HBV mouse models have initially relied on hydrodynamic tail vein injection to achieve high-level hepatocyte transfection. This method employs rapid, high-volume injection of a nucleic acid solution through the mouse tail vein. The build up of hydrostatic pressure in the inferior vena cava forces the nucleic acid solution into a number of different organs with the highest uptake observed in hepatocytes of liver. Up to 40% of liver hepatocytes can be transfected with the bulk of the DNA taken up by hepatocyte nuclei (Lui et al., 1999; Zhang et al., 2004a) .When multiple nucleic acid molecules are co-administered by hydrodynamic injection, colocalization of these molecules within the same subset of hepatocytes occurs with high frequency, making co-transfection with multiple nucleic acid molecules possible. Using this mode of delivery, a number of groups have demonstrated that co-transfection of HBV expression plasmids with anti-HBV siRNA or shRNA expression plasmids can downregulate HBV antigen production and HBV replication in vivo. Using this approach, Giladi et al. (2003) and Klein et al. (2003) have shown that unmodified siRNAs directed against HBV core and surface antigen mRNAs had significant dose-dependent effects on HBV expression in immunocompetent mice. Other groups have demonstrated that expressed siRNAs derived from pol III-driven shRNAcontaining plasmids are also effective in hydrodynamic co-transfection experiments (McCaffrey et al., 2003; Wu et al., 2005) . Additionally, McCaffrey et al. (2003) showed this effect in both immunodeficient and immune competent mice, indicating that B and T-cell function were not required for the expressed siRNA anti-HBV activity. The use of immunodeficient mice, allows longterm expression of HBV (Yang et al., 2002) .
Non-hydrodynamic delivery. The above studies all demonstrate the in vivo effectiveness of RNAi against HBV when hydrodynamic injection is employed to deliver the effector RNAs and DNAs to hepatocytes. To be therapeutically viable however, clinically relevant delivery modalities must be developed. Because rapid degradation of unmodified RNA (Soutschek et al., 2004; Morrissey et al., 2005a) and to a lesser extent DNA (Kawabata et al., 1995) in serum by serum nucleases occurs, improving serum stability is key in the development of systemic delivery systems for nucleic acids. Morrissey et al. (2005a) used hydrodynamic injection of an infectious HBV clone to establish virus expression in hepatocytes of C57BL/J6 mice. This was followed 72 h later by standard i.v. injection of 2 0 -OH-modified siRNA duplexes targeting HBV RNAs. The 2 0 -OHmodification has been shown to increase siRNA stability. A reduction of serum HBV DNA levels by 0.90 log 10 was observed at the highest dose of the modified siRNA, whereas no statistically significant reduction was seen using standard i.v. injection of the unmodified siRNAs. These results highlight some of the difficulties and promise surrounding delivery of RNAibased drugs to the liver; although less than 1% of the administered modified siRNA reached the liver when both a high dose and frequent dosing regime were used, the transfected siRNAs still exerted an anti-viral effect. (Morrissey et al., 2005b) later showed that formulating the 2 0 -OH modified siRNAs with specialized liposome compositions resulted in siRNA lipid particles with increased serum stability. In these studies** hydrodynamic delivery of an HBV plasmid was used to establish HBV expression in immunodeficient mice. Six days posthydrodynamic injection, the liposome-formulated modified HBV-specific siRNA, was administered by i.v. injection. A dose dependent reduction of both serum HBV DNA and HBsAg was observed for up to 7 days post i.v. injection. Formulation of the siRNA in a lipid particle allowed the use an B30-fold lower dose compared to the dose used in the previous study and achieved a more significant reduction in HBV expression (Morrissey et al., 2005a) . Although these improvements are significant, the extrapolated dose and dosing frequency for humans are not clinically relevant. Soutschek et al. (2004) have also demonstrated the increased stability and efficacy of chemically modified siRNAs delivered by i.v. injection. Cholesterol modified siRNAs directed against the endogenous apolipoprotein B (apoB) gene product were able to significantly reduce expression of the apoB gene product and lower blood cholesterol levels in a transgenic mouse model. As with the results of Morrissey et al. (2005b) further optimization of these modified siRNAs is required to achieve potency and dosing that will make them viable for therapeutic use.
In an HBV transgenic mouse model mimicking chronic infection, (Uprichard et al., 2005) have shown that pol III driven siRNA delivered to the liver by recombinant adenovirus suppressed preexisting HBV gene expression and replication for at least 26 days. These results demonstrate the potential of viral vectors for delivery to the liver and long-term RNAi-mediated suppression of target messages when expression systems are used to produce intracellular siRNAs. This longterm expression of siRNA is not only applicable for therapeutic use but may also enable the use of expressed RNAi for prophylaxis against virus infection when administered before viral exposure.
The advantages presented by using a vectored approach to express siRNA have led Nucleonics to develop multi-cistronic plasmids in which a number of distinct siRNAs are produced from a single vector. Expressing multiple HBV-specific shRNAs from a single plasmid allows effective siRNAs to be produced in the cell at a higher and more uniform dose level over longer periods, and thus provides insurance against potential escape mutants. A prototype HBV vector (containing four HBV-specific siRNAs) has been extensively tested in a cell culture system in which an HBV replicon has been reproducibly inhibited with a calculated IC50 in the sub-femtomolar range. As predicted, the ability of this vector to downregulate both viral replication and viral antigenemia (both sAg and eAg) has been demonstrated ( Figure 3) . Experiments in mouse models also indicate that this vector is effective in an in vivo setting. Stability and hepatocyte cell targeting properties are conferred to the plasmid DNA through complexation with ligand modified spermine molecules. Using the spermine-based delivery system, the prototype HBV vector was successfully delivered to mouse hepatocytes where downregulation of HBV proteins and RNA was achieved at levels comparable to those obtained using hydrodynamic delivery. The ability of this multicistronic vector to work effectively and the ability to target desired cell types using appropriately ligand modified spermines provides evidence for a platform technology that can be used against a variety of viral pathogens.
RNA interference as a therapy for chronic hepatitis C virus infection

Hepatitis C virus replication
Infection with HCV is a serious public health problem worldwide. It is estimated that 2-3% of the world population is chronically infected with HCV. There are approximately six HCV genotypes, whose sequences vary as much as 51% between the different strains (Bukh et al., 1995; Simmonds, 1999) . Each genotype consists of multiple variations or quasispecies (Enomoto et al., 1995) . Identifying siRNAs that effectively target conserved HCV sequences will therefore be key to the development of RNAi-based HCV therapeutics.
Genotypes 1a and 1b are the predominant genotypes found in North and South America and Europe, whereas 1b is the predominant HCV genotype in Asia (Chayama et al., 1995) . Hepatitis C virus, a hepacivirus, is a member of the Flaviviridae family. The viral genome is a single-stranded, positive-sense RNA of B9.6 kb, that functions as the only viral mRNA encoding a single polyprotein of B3000 amino acids that is processed into structural proteins (core, p7, and the envelope proteins E1 and E2) and nonstructural (NS) proteins (NS2, NS3, NS4A and B, and NS5A and B) (Figure 4 ) (reviewed in Bartenschlager and Lohmann, 2000) . A negative strand replicative intermediate is also produced in cells at lower levels than the plus strand RNA. This means that there is only a single plus strand species that can be targeted by RNAi.
The in vitro study of HCV has relied on the use of HCV subgenomic ( Figure 5 ) and genomic replicons that replicate autonomously in human heptatoma cells (Huh7 cells) (Lohmann et al., 1999; Blight et al., 2002) . Commonly used genomic and subgennomic HCV replicons are bicistronic constructs, where the HCV 5 0 -UTR-IRES (internal ribosome entry site) directs expression of the neomycin phosphotranferase gene (neo) followed by the encephalomyocarditis virus (ECMV) IRES directing expression of HCV gene products and terminating with the HCV 3 0 -UTR. Inclusion of the neo gene allows for selection of transformants and stable propagation of repliconcontaining cell lines.
Challenges to the development of RNA interference-based therapeutics The variability of the HCV genome presents significant challenges to the design of therapeutics that effectively suppress HCV infection. Hepatitis C virus encodes a RNA-dependent RNA polymerase (NS5B) with a higherror rate. This low fidelity replication machinery results in the production of virus 'quasispecies', which contain an average of approximately one nucleotide change per replication cycle . Successful anti-HCV therapeutics must have the inherent ability to see and inhibit replication of viral variants and prevent the generation of virus escape mutants. As the efficacy of an A duplicate set of transfected Huh7 cells (as described in a) was lysed and subjected to Western blot analysis. Viral Large (L) and Middle (M) surface proteins were probed using rabbit anti-HBV PreS2 antibody, followed by incubation with goat anti-rabbit IgG antibody conjugated with horseradish peroxidase. Bands were visualized using chemiluminescence. Because of glycosylation, the HBV Large protein shows two bands of 42 and 39 kd., whereas the Middle protein exhibits a triplets of 36, 33 and 30 kd.
siRNA for a specific target is directly related to sequence homology, the use of RNAi therapy to combat HCV infection will need to incorporate sequence design paradigms which can circumvent the plasticity of the HCV genome.
Research into anti-HCV drug development has been hampered by the lack of robust cell culture infection systems and accessible animal models to test drug efficacy. A major step towards studying HCV has recently been achieved with the development of stable HCV cell culture models, which permit robust production of infectious HCV particles (Cai et al., 2005; Lindenbach et al., 2005; Wakita et al., 2005; Zhong et al., 2005) . These new reagents will aid in the study and design of anti-HCV therapies. Previous HCV work using RNAi has focused on the use of HCV-reporter fusion systems, and subgenomic and genomic HCV replicon models (Lohmann et al., 1999; Blight et al., 2000 Blight et al., , 2002 Kro¨nke et al., 2004) . Using an HCV NS5B gene target sequence fused to a luciferase reporter, McCaffrey et al. (2002) used co-hydrodynamic injection of the reporter fusion along with anti-NS5B siRNAs or polIII produced anti-NS5B shRNAs to show knockdown of luciferase expression in mice, demonstrating in vivo functionality of the anti-HCV siRNA. Other groups have used the sub-genomic replicon system and demonstrated siRNA efficacy against established replicating HCV RNA. Kapadia et al. (2003) showed significant inhibition of HCV RNA and protein expression with siRNAs targeting NS3 and NS5B. This downregulation was independent of an interferon response. Yokota et al. (2003) used a similar system to test the efficacy of siRNA sequences targeted to the HCV 5 0 -UTR which is one of the most conserved regions of the HCV genome. They also designed pol III driven expression constructs producing shRNA derived siRNAs and constructs producing sense and anti-sense RNA. Sequence specific effectiveness was found indicating that secondary structure within the 5 0 -UTR target impacts RNAi efficacy, and that plasmids expressing shRNA work better than plasmids producing sense and anti-sense transcripts. Using a full length replicon system, Randall et al. (2003) found that siRNAs directed to the 5 0 -UTR region cleared replicating HCV RNA from >98% of the cell culture to below detectable levels. This effect was dose dependent and specific in that nucleotide changes within the target siRNA sequence abolished the effect. Wilson et al. (2003) showed that long term suppression of HCV RNA replication could be established. Using episomal plasmids expressing pol III driven sense and antisense transcripts against NS5B, inhibition of HCV RNA replication was maintained for up to 3 weeks. Interestingly, synthetic siRNAs against NS5B inhibited ( þ ) and (À) strand HCV RNA replication, indicating that both the genome strand and the anti-genome strand may be targets for RNAi and/or that targeting one of the strands has a downstream negative effect on production of the other strand. Prabhu et al. (2005) also showed siRNA mediated inhibition of both ( þ ) and (À) strand HCV RNA synthesis. High level expression of HCV RNA was achieved using T7 polymerase driven expression of a full-length HCV cDNA clone. Polymerase III driven expression of shRNAs directed against the E2, NS3 and NS5B regions of the HCV genome inhibited gene expression as well as production of both the genome and antigenome strands of HCV. Wilson and Richardson (2005) have shown that HCV replicon escape mutants can emerge after multiple siRNA treatments. An 87% reduction of HCV replicon replication and gene expression was previously shown (Wilson et al., 2003) when replicon expressing cells were transfected with an siRNA targeting the NS5B gene. Mutations, speculated to have occurred in the HCV RNA, were thought to be selected for after siRNA treatment. In a follow-up study, HCV escape mutations were shown to have indeed occurred. After one treatment with the anti-NS5B siRNA, HCV genomes were identified that contained mutations within the siRNA target sequence. A single mutation in the target sequence had a minimal effect on the efficacy of the siRNA, leading to a 4 or 13% loss of activity. After five consecutive siRNA treatments, genomes were identified that contained multiple point mutations within the siRNA target sequence, and the addition of a second point mutation within the target sequence led to a 70-80% loss of siRNA activity. This occurred when two individual siRNAs targeting different regions within NS5B were used. Interestingly, when the two anti-NS5B siRNAs were co-transfected simultaneously into replicon containing cells, resistance was barely detectable. These results indicate that simultaneous targeting of multiple HCV sequences may be one method to avoid the generation of escape mutations in this highly mutable virus. Another observation made from these studies was that siRNAs co-transfected with HCV replicon RNA had a greater efficacy (97-99% inhibition) than siRNAs transfected into cells stably expressing the HCV replicon (90% inhibition), suggesting that RNAi may be useful as a prophylactic to protect uninfected cells from HCV infection.
In addition to targeting viral RNAs, it may be possible to inhibit HCV replication by targeting the expression of cellular proteins needed for HCV replication. Several cellular proteins have been identified as cofactors that effect HCV replication by interacting with the 5 0 and 3 0 untranslated regions of the HCV genome. Korf et al. (2005) have shown that pol III driven shRNAs targeted to either the HCV-5 0 -UTR or the 3 0 -UTR are efficient at downregulating HCV replicon replication. Additionally, the cellular co-factors, proteosome a-subunit 7 (PSMA7), which modulates HCV-IRES (Kruger et al., 2001 ) activity in cell culture, and HU antigen R (HuR), which interacts with the HCV 3 0 -UTR (Spangberg et al., 2000) , were targeted by pol III driven shRNAs in replicon expressing cells. Short interfering RNA knock-down of these endogenous gene products effectively inhibited HCV replicon replication in Huh7 cells. Furthermore, combinations of siRNAs against PMSA7, HuR along with anti-HCV siRNAs exhibited additive effects leading to enhanced decreases in HCV RNA levels. It remains to been seen whether there are any deleterious effects associated with downregulation of these host cell proteins. These results, however, along with the work of Wilson and Richardson (2005) indicate that combination siRNA therapies may be an effective way to increase the efficacy of therapeutic siRNAs and decrease the potential of generating drug resistant mutations.
Endogenous RNA interference targets for treatment of Hepatocellular carcinoma. The targeting of HBV and HCV transcripts provides one avenue by which HCC can be treated. However, the potential for reducing or eliminating the intracellular expression of selected genes and proteins using RNAi also makes this technology attractive for the treatment of endogenous targets within HCC cells. Whereas many of the same challenges will be associated with the knock-down of endogenous host genes as with viral genes, additional questions will need to be addressed before RNAi can be used to attack HCC via the reduction of particular endogenous mRNAs.
The complex nature of HCC has made the assignment of genes associated with this disease difficult to generalize. As with other types of malignancy, the stage of disease will influence the panoply of genes that are up or down regulated at any given time. The typical patient presents at a late stage that may provide additional obstacles to delivery of the effector molecule and the efficacy with which it acts.
Because of the limited therapeutic options available for patients with HCC, numerous groups have searched for molecules that are upregulated in HCC cells and may provide attractive therapeutic targets. Comparison of the transciptome and proteome of HCC cells with healthy liver cells has indeed indicated that a variety of messages and proteins are present to a greater degree in HCC cells (Blanc et al., 2005; Mao et al., 2005; Wong et al., 2005) . However, the particular transcripts and/or proteins that are increased sometimes vary among the individual studies. Not surprisingly, growth factors such as epidermal growth factor (EGF) and its receptor (EGFR) as well as angiogenic factors such as vascular endothelial growth factor (VEGF) are often found in increased amounts in HCC cells (Suzuki et al., 1996; Miura et al., 1997; Hisaka et al., 1999) . An increase in the activity of the mitogen activated protein kinase (MAPK) pathway is also seen in a large percentage of HCC cells (Schmidt et al., 1997; Ito et al., 1998) .
Therefore, RNAi is an obvious candidate for the treatment of patients with HCC through the downregulation of proteins associated with malignant cells. The data of Song et al., in which siRNAs targeting the Fas gene decreased hepatitis in mice, suggest that this approach may indeed be applicable in an in vivo setting (Song et al., 2003) . Unfortunately, the variable nature of HCC may make it difficult to identify a single protein that will be responsible for all (or even most) cases of HCC. It may be necessary to deliver a number of different effector molecules to cover as many potentially causative transcripts as possible. This may be accomplished through a cocktail of siRNAs or through the use of a multi-cistronic plasmid expressing a number of shRNAs. Additional studies that more clearly identify these endogenous targets will aid in the design of these effectors.
